REPL earnings: real EPS beat/miss history, analyst consensus Buy, P/E -3.18. Updated 2026-07-23.
Replimune Group (REPL) Research Hub
Replimune Group (REPL) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 12.92 USD (-10.59%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -3.18, market cap 0.92B. This hub links to the full technical, earnings and options research available for REPL.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 12.92 USD (-10.59%) |
| 52-week range | 4.76 USD – 16.02 USD |
| Trend regime | Range |
| 14-day RSI | 55.2 (Bullish) |
| Trailing P/E | -3.18 |
| Market cap | 0.92B |
| Dividend yield | 0.00% |
Available research for REPL
Covered Call on REPL: how it works, illustrative setup around the real 12.92 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on REPL: how it works, illustrative setup around the real 12.92 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on REPL: how it works, illustrative setup around the real 12.92 USD price, max profit/loss, breakeven and when to use it. Educational.
REPL technical analysis: range, last 12.92 USD, RSI 55.2, 52w range 4.76 USD–16.02 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is REPL in?
Replimune Group (REPL) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is REPL in an uptrend or downtrend?
As of 2026-09-11, REPL is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is REPL's trailing P/E ratio?
REPL's trailing P/E is -3.18, with a market cap of 0.92B. See the earnings research page for full valuation detail.